patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug
luspatercept
Marketedupdated 2mo agoby Celgene Corp
Approvedcommunity read0 votes
all catalysts(6)
approval · 6
Nov 8, 2019
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Apr 3, 2020
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Jul 8, 2022
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Aug 28, 2023
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
May 16, 2024
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
Feb 27, 2026
approval
REBLOZYL (LUSPATERCEPT-AAMT) — FDA approval
luspatercept
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that